TNFRSF8 and triple-negative breast carcinoma: Four patients received ICIs in combination with other drugs, including two with non-Hodgkin lymphoma who were treated with rituximab and brentuximab vedotin, which respectively target CD20 and CD30, one with NSCLC who was treated with glucocorticoids and pembrolizumab, and one with triple-negative breast cancer who received paclitaxel with atezolizumab.